|  
         
      GOOD DAYS from CDF Patient Assistance Program
      Patient assistance programs (PAPs) are programs created by drug companies,
	  such as GOOD DAYS from CDF, to offer free or low cost drugs to individuals who are unable to
	  pay for their medication.  These Programs may also be called indigent drug programs, 
	  charitable drug programs or medication assistance programs.  Most of the best known and
	  most prescribed drugs can be found in these programs.  All of the major drug companies
	  have patient assistance programs, although every company has different eligibility and 
	  application requirements. 
      The GOOD DAYS from CDF patient assistance program offers free medication to people
	  who otherwise cannot afford their medications.  Patients must meet financial and other
	  program specific criteria to be eligible for assistance.  
	  
	  To find out how to apply for medication assistance from the GOOD DAYS from CDF patient
	  assistance program, visit our Patient Center and use our Database to search for the medication needed. 
	   
	  
	  For a complete listing of GOOD DAYS from CDF medications available through 
	  their patient assistance programs, see below: 
	  
                                        					
							
						
						Good Days Program
						
						 | 
					 
					
					|       | 
					The medications available through this program are:
					 |  
                                        					
						|       | 
						
						
													
							|   Agrylin
							(anagrelide hydrochloride) | 
							 
												 
						 | 
					 
                                        					
						|       | 
						
						
													
							|   Aptivus capsules
							(tipranavir) | 
							 
												 
						 | 
					 
                                        					
						|       | 
						
						
													
							|   Atripla
							(efavirenx/emtricitabine/tenofovir disoproxil fumarate) | 
							 
												 
						 | 
					 
                                        					
						|       | 
						
						
													
							|   Beovu
							(brolucizumab-dbll) | 
							 
												 
						 | 
					 
                                        					
						|       | 
						
						
													
							|   Biktarvy
							(bictegravir/emtricitabine/tenofovir alafenamide) | 
							 
												 
						 | 
					 
                                        					
					
					
						| 
						  
						 | 
					 
                                        			  
      
     |